EE200000148A - Kay - uus immuunsüsteemi valk - Google Patents

Kay - uus immuunsüsteemi valk

Info

Publication number
EE200000148A
EE200000148A EEP200000148A EEP200000148A EE200000148A EE 200000148 A EE200000148 A EE 200000148A EE P200000148 A EEP200000148 A EE P200000148A EE P200000148 A EEP200000148 A EE P200000148A EE 200000148 A EE200000148 A EE 200000148A
Authority
EE
Estonia
Prior art keywords
kay
immune system
new protein
protein
new
Prior art date
Application number
EEP200000148A
Other languages
English (en)
Estonian (et)
Inventor
Tschopp Jurg
Original Assignee
Biogen, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Incorporated filed Critical Biogen, Incorporated
Publication of EE200000148A publication Critical patent/EE200000148A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
EEP200000148A 1997-09-12 1998-09-11 Kay - uus immuunsüsteemi valk EE200000148A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5878697P 1997-09-12 1997-09-12
PCT/US1998/019037 WO1999012964A2 (en) 1997-09-12 1998-09-11 Kay - a novel immune system protein

Publications (1)

Publication Number Publication Date
EE200000148A true EE200000148A (et) 2001-02-15

Family

ID=22018915

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000148A EE200000148A (et) 1997-09-12 1998-09-11 Kay - uus immuunsüsteemi valk

Country Status (17)

Country Link
EP (1) EP1012270A2 (no)
JP (1) JP2001515711A (no)
KR (1) KR20010023892A (no)
CN (1) CN1269832A (no)
AU (1) AU9315298A (no)
BR (1) BR9812433A (no)
CA (1) CA2303424A1 (no)
EA (1) EA200000311A1 (no)
EE (1) EE200000148A (no)
HU (1) HUP0004034A3 (no)
IL (1) IL134480A0 (no)
IS (1) IS5375A (no)
NO (1) NO20001240L (no)
PL (1) PL339740A1 (no)
SK (1) SK3532000A3 (no)
TR (1) TR200000654T2 (no)
WO (1) WO1999012964A2 (no)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
WO1999026463A2 (en) * 1997-11-26 1999-06-03 Eli Lilly And Company Tnf ligand family gene
US6297367B1 (en) 1997-12-30 2001-10-02 Chiron Corporation Polynucleotide encoding TNFL1
AU2093499A (en) * 1997-12-30 1999-07-19 Chiron Corporation Members of tnf and tnfr families
WO2001060397A1 (en) 2000-02-16 2001-08-23 Genentech, Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
GB9828628D0 (en) 1998-12-23 1999-02-17 Glaxo Group Ltd Novel ligand
US7833529B1 (en) 1999-01-07 2010-11-16 Zymogenetics, Inc. Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
DK1146892T3 (da) 1999-01-25 2003-11-24 Apoxis Sa BAFF, inhibitorer deraf og deres anvendelse i modulationen af B-celle responset
US20030095967A1 (en) 1999-01-25 2003-05-22 Mackay Fabienne BAFF, inhibitors thereof and their use in the modulation of B-cell response and treatment of autoimmune disorders
US6475986B1 (en) 1999-02-02 2002-11-05 Research Development Foundation Uses of THANK, a TNF homologue that activates apoptosis
NZ513290A (en) * 1999-02-23 2004-05-28 Human Genome Sciences Inc Neutrokine-alpha and neutrokine-alpha splice variant
US20030022233A1 (en) 1999-04-30 2003-01-30 Raymond G. Goodwin Methods of use of the taci/taci-l interaction
WO2000068378A1 (en) * 1999-05-06 2000-11-16 National Jewish Medical And Research Center Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof
IL148089A0 (en) * 1999-08-17 2002-09-12 Biogen Inc Baff receptor (bcma), an immunorgulatory agent
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
AU3495301A (en) 2000-02-11 2001-08-20 Biogen Inc Heterologous polypeptide of the tnf family
AU2001261557B2 (en) 2000-05-12 2005-06-30 Amgen Inc. Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci
WO2002002641A1 (en) 2000-06-16 2002-01-10 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to blys
US7220840B2 (en) 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
EP1309718A4 (en) * 2000-08-15 2004-08-25 Human Genome Sciences Inc NEUTROKINE-ALPHA AND NEUTROKINE-ALPHA SPLICE VARIANT
AU2001288301A1 (en) 2000-08-18 2002-03-04 Human Genome Sciences, Inc. Binding polypeptides and methods based thereon
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EE05294B1 (et) 2001-05-11 2010-04-15 Amgen Inc. TALL-1-ga seostuv ainekompositsioon
AR035119A1 (es) 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
NZ543174A (en) 2003-03-28 2008-09-26 Biogen Idec Inc Truncated BAFF receptors
ES2537738T3 (es) 2003-06-05 2015-06-11 Genentech, Inc. Terapia de combinación para trastornos de células B
RU2006117324A (ru) 2003-10-20 2007-12-10 Байоджен Айдек Ма Инк. (Us) Терапевтические режимы для антагонистов baff
AU2004315198A1 (en) * 2004-01-29 2005-08-18 Genentech, Inc. Variants of the extracellular domain of BCMA and uses thereof
BRPI0516297A (pt) 2004-10-05 2008-09-02 Genentech Inc métodos de tratamento de vasculite e artigos de fabricação
EP2332563A3 (en) 2004-10-13 2013-03-13 The Washington University Use of BAFF to treat sepsis
JP2008525002A (ja) 2004-12-23 2008-07-17 ラボラトワール セローノ ソシエテ アノニム Ｂｃｍａポリペプチド及びその使用
WO2007019573A2 (en) 2005-08-09 2007-02-15 Zymogenetics, Inc. Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
EA016083B1 (ru) 2005-08-09 2012-02-28 Займоджинетикс, Инк. СПОСОБ ЛЕЧЕНИЯ НЕХОДЖКИНСКОЙ ЛИМФОМЫ С ПОМОЩЬЮ СЛИТОЙ МОЛЕКУЛЫ TACI-Ig
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
JP6088723B2 (ja) 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
US8211649B2 (en) 2006-03-31 2012-07-03 Human Genome Sciences, Inc. Methods of diagnosing and prognosing hodgkin's lymphoma
CN101489573B (zh) 2006-05-15 2013-05-22 阿雷斯贸易股份有限公司 用TACI-Ig融合分子治疗自身免疫疾病的方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
WO2011028945A1 (en) 2009-09-03 2011-03-10 Genentech, Inc. Methods for treating, diagnosing, and monitoring rheumatoid arthritis
BR112013021725A2 (pt) 2011-02-28 2016-11-01 Genentech Inc marcadores biológicos e métodos para prever resposta aos antagonistas de células b
JP2016507523A (ja) 2013-02-05 2016-03-10 エンクマフ アーゲー ＣＤ３εおよびＢＣＭＡに対する二重特異的抗体
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
EP3129380B1 (en) 2014-04-11 2018-11-28 Boehringer Ingelheim International Gmbh Spiro[3h-indole-3,2'-pyrrolidin]-2(1h)-one derivatives and their use as mdm2-p53 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994018325A1 (en) * 1993-02-03 1994-08-18 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
AU6166396A (en) * 1995-06-07 1996-12-30 Biogen, Inc. Complexes of modified lymphotoxins as pharmaceutical prepara tions
ATE302272T1 (de) * 1996-10-25 2005-09-15 Human Genome Sciences Inc Neutrokin alpha
AU5705898A (en) * 1996-12-17 1998-07-15 Schering Corporation Mammalian cell surface antigens; related reagents
CA2232743A1 (en) * 1997-04-02 1998-10-02 Smithkline Beecham Corporation A tnf homologue, tl5

Also Published As

Publication number Publication date
KR20010023892A (ko) 2001-03-26
NO20001240D0 (no) 2000-03-09
IS5375A (is) 2000-02-11
JP2001515711A (ja) 2001-09-25
NO20001240L (no) 2000-05-10
AU9315298A (en) 1999-03-29
EA200000311A1 (ru) 2000-10-30
WO1999012964A3 (en) 1999-05-27
BR9812433A (pt) 2000-09-26
SK3532000A3 (en) 2001-12-03
IL134480A0 (en) 2001-04-30
PL339740A1 (en) 2001-01-02
HUP0004034A3 (en) 2002-08-28
TR200000654T2 (tr) 2000-07-21
HUP0004034A2 (en) 2001-03-28
CA2303424A1 (en) 1999-03-18
CN1269832A (zh) 2000-10-11
WO1999012964A2 (en) 1999-03-18
EP1012270A2 (en) 2000-06-28

Similar Documents

Publication Publication Date Title
EE200000148A (et) Kay - uus immuunsüsteemi valk
ATE324456T1 (de) Proteinexpression in baculovirus-vektor expressionsystemen
DE69704309D1 (de) Verbinder
DE69821928D1 (de) Intrakardiales defibrillierungssystem
DE69705170D1 (de) Verbinder
DE69822740D1 (de) Verbinder
DE69819057D1 (de) Verbinder
DE69734745D1 (de) Verbinder
DE69727259D1 (de) Flugzeug
DE69834906D1 (de) Verbinder
NO985680D0 (no) Peptidderivater
DE69829560D1 (de) Verbinder
DE59710258D1 (de) Verbindungsbeschlag
DE59710022D1 (de) Prozessor mit Pipelining-Aufbau
NO983849L (no) Peptidderivater
DE59705833D1 (de) Biaxialmischer
DE69723647D1 (de) Verbinder
NO963487D0 (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
DK0865832T3 (da) Sorteringssystem
DE69823611D1 (de) Verbinder
DE69838828D1 (de) Verbinder
ITPD970221A0 (it) Impianto frigorifero
DE69737872D1 (de) Verbinder
DE69705463D1 (de) Verbinder
DE59608090D1 (de) Ansaugsystem